Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$149,347.00

Nanoparticle-based anti-Myc cancer therapeutics

FY 2016-17

Summary
We are designing new drugs that can combat cancer. These drugs are based on natural proteins, which are abundant inyour body and make your body function. We take these building blocks and design super protein drugs. One of our drugsinterferes with a known problem in cells that can lead to cancer. Our team is now focusing on how to use nanotechnology,which are tiny carrier particles that can deliver the drug to cancer cells. Once inside the cells, the drug can interfere withcancer networks. We have shown that our strategy can work in human cancer cell experiments, and we are now aiming totest our drugs in mice. The Canadian company BioVectra is our partner and is involved in our studies with the hope ofadvancing our new drug to human cancer patients. They are also excited to work with us, because we can take the conceptsdescribed in this work and design additional drugs targeting other proteins that cause problems in many human diseases.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
462505-2014
Name nom
Shin, Jumi
Department département
Chemical and Physical Sciences (Mississauga)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2014
Award amount
149347
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
3
Nb partie
3
Application title
Nanoparticle-based anti-Myc cancer therapeutics
Keyword
NSERC
Application summary
We are designing new drugs that can combat cancer. These drugs are based on natural proteins, which are abundant inyour body and make your body function. We take these building blocks and design super protein drugs. One of our drugsinterferes with a known problem in cells that can lead to cancer. Our team is now focusing on how to use nanotechnology,which are tiny carrier particles that can deliver the drug to cancer cells. Once inside the cells, the drug can interfere withcancer networks. We have shown that our strategy can work in human cancer cell experiments, and we are now aiming totest our drugs in mice. The Canadian company BioVectra is our partner and is involved in our studies with the hope ofadvancing our new drug to human cancer patients. They are also excited to work with us, because we can take the conceptsdescribed in this work and design additional drugs targeting other proteins that cause problems in many human diseases.
University of Toronto - $149,347 Grant (2016-17) | Canada Spends